Program
isatuximab
Also written as “Isatuximab SAR650984”, “Isatuximab” and “isatuximab SAR650984”.
Its studies are mostly in Multiple Myeloma · Lymphoma · Immune System Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 215 open or running | phase 3since Dec 4, 2016 | Mar 9, 2010 | Apr 5, 2027phase 3 · NCT03319667 |
| GlaxoSmithKline | 11 open or running | phase 2since Oct 13, 2025 | Oct 13, 2025 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since May 31, 2018 | May 31, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Mar 9, 2010.
- May 31, 2018Hoffmann-La Roche's first study: phase 2 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT03555149 · 96 enrolled · United States, Australia, France and more
- Aug 5, 2018Phase 2 study in NeoplasmsSanofi · NCT03637764 · 107 enrolled · United States, Belgium, Canada and more
- Oct 31, 2018Phase 1 study in Multiple MyelomaSanofi · NCT03733717 · 25 enrolled · China
- Nov 29, 2018Phase 2 study in LymphomaSanofi · NCT03769181 · 58 enrolled · France, Italy, Netherlands and more
- Feb 21, 2019Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaSanofi · NCT03860844 · 67 enrolled · United States, Argentina, Brazil and more
- Aug 2, 2019Phase 1 study in Multiple MyelomaSanofi · NCT04045795 · 56 enrolled · United States, Australia, Belgium and more
- Feb 13, 2020Phase 3 study in Multiple MyelomaSanofi · NCT04270409 · 337 enrolled · United States, Australia, Brazil and more
- Feb 19, 2020Phase 2 study in Immune System DiseasesSanofi · NCT04294459 · 23 enrolled · United States, Spain
- Dec 1, 2020Phase 2 study in Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi · NCT04661033 · 8 enrolled · United States, France, Germany and more
- May 31, 2022Phase 3 study in Plasma Cell Myeloma RecurrentSanofi · NCT05405166 · 531 enrolled · United States, Argentina, Australia and more
- Dec 20, 2022Phase 2 study in Multiple MyelomaSanofi · NCT05669989 · 70 planned · United States, Australia, Brazil and more
- Jan 20, 2023Phase 2 study in Multiple MyelomaSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Oct 13, 2025GlaxoSmithKline's first study: phase 2 study in Multiple MyelomaNew to GlaxoSmithKlineGlaxoSmithKline · NCT07217184 · 30 enrolled · United States, Australia, Brazil and more
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 5, 2027Primary completion: phase 3 study in Multiple MyelomaSanofi · NCT03319667
- Nov 30, 2028Primary completion: phase 2 study in Multiple MyelomaSanofi · NCT05669989
- Oct 14, 2030Primary completion: phase 3 study in Multiple MyelomaSanofi · NCT04270409
TargetBeta
“A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07217184Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 30 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Sanofi | Dec 22, 2025 | 118 |
| NCT05669989Multiple Myeloma · United States, Australia, Brazil and more | 2 | By invitation | Sanofi | Nov 30, 2028 | 70 |
| NCT05405166Plasma Cell Myeloma Recurrent · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sanofi | Nov 6, 2024 | 531 |
| NCT04661033Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, France, Germany and more | 2 | Terminated | Sanofi | Jun 26, 2023 | 8 |
| NCT04294459Immune System Diseases · United States, Spain | 2 | Terminated | Sanofi | May 2, 2022 | 23 |
| NCT04270409Multiple Myeloma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Sanofi | Oct 14, 2030 | 337 |
| NCT04045795Multiple Myeloma · United States, Australia, Belgium and more | 1 | Completed | Sanofi | Mar 27, 2024 | 56 |
| NCT03860844Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Argentina, Brazil and more | 2 | Terminated | Sanofi | Sep 12, 2022 | 67 |
| NCT03769181Lymphoma · France, Italy, Netherlands and more | 2 | Terminated | Sanofi | Nov 8, 2022 | 58 |
| NCT03733717Multiple Myeloma · China | 1 | Completed | Sanofi | Sep 6, 2020 | 25 |
| NCT03637764Neoplasms · United States, Belgium, Canada and more | 2 | Terminated | Sanofi | May 11, 2022 | 107 |
| NCT03555149Colorectal Neoplasms · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Sep 26, 2022 | 96 |
| NCT03367819Prostatic Neoplasms · United States, France, Italy and more | 2 | Terminated | Sanofi | Mar 10, 2021 | 44 |
| NCT03319667Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sanofi | Apr 5, 2027 | 475 |
| NCT02999633Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · United States, Finland, France and more | 2 | Terminated | Sanofi | Nov 14, 2017 | 14 |
| NCT02990338Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Sanofi | Nov 22, 2018 | 307 |
| NCT02812706Multiple Myeloma · Japan | 2 | Completed | Sanofi | Jul 31, 2018 | 36 |
| NCT02514668Multiple Myeloma · United States, Czechia, France | 1 | Completed | Sanofi | Dec 2, 2021 | 55 |
| NCT02513186Multiple Myeloma · France, Germany, Italy and more | 1 | Completed | Sanofi | Jan 28, 2022 | 90 |
| NCT02283775Multiple Myeloma · United States | 1 | Completed | Sanofi | May 26, 2021 | 54 |
| NCT01749969Multiple Myeloma · United States | 1 | Completed | Sanofi | Jun 20, 2023 | 57 |
| NCT01084252Hematologic Neoplasms · United States, Argentina, Belgium and more | 2 | Completed | Sanofi | Dec 21, 2018 | 351 |
How it is read
Names in the registry
- “Isatuximab SAR650984”, 11 entries
- “Isatuximab”, 6 entries
- “isatuximab SAR650984”, 3 entries
- “Isatuximab intravenous (IV)”, 1 entry
- “Isatuximab subcutaneous (SC)”, 1 entry
Codes read as this program: SAR650984.
Conditions, from the studies’ own filings
- Multiple Myeloma, 14 studies
- Lymphoma, 1 study
- Immune System Diseases, 1 study
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Anemia, Hemolytic, Autoimmune, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.